In the OlympiA trial (NCT02032823), adjuvant olaparib significantly enhanced invasive and distant disease-free survival in patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 mutations, compared to a placebo. This evidence concerns the gene ERBB2 and breast carcinoma.